Consolidated Financial Result Briefing
for the nine months ended December 31, 2024 CYBERDYNE Inc.
February 13, 2025
Consolidated nine months result summary (IFRS)
(Unit: Millions of yen) | 2023/3Q | 2024/3Q | +/- | +/- |
Revenue | 3,219 | 3,169 | -49 | -1.5% |
Core operating profit (loss) | -999 | -584 | + 415 | - |
Operating profit (loss) | -1,603 | -708 | + 895 | - |
Profit (loss) before tax | -566 | -297 | + 269 | - |
Profit (loss) attributable to | -951 | -384 | + 567 | - |
owners of parent | ||||
・Treatment service (RHG etc.) +106 Million (Business +29, Foreign exchange +77) | ||||
3,169 Million | ||||
Revenue | ・Product Rental (Domestic, APAC) +50 Million (Business +27, Foreign exchange +23) | |||
YoY -49 Million（-1.5%） | ・Product Rental (EMEA, US) -42 Million (Business -58, Foreign exchange +15) | |||
・New business expansion (German: LeyLine) -163 Million (Business -188, Foreign exchange +25) | ||||
Core Operating | - 584 Million | ・Treatment Service (RHG etc.) +257 Million (FY24: -97, FY23: -354 ) | ||
・Product Rental -95 Million (FY24: 504, FY23: 599) | ||||
Profit | YoY + 415 Million | ・New business expansion (three subsidiaries) +40 Million (FY24: -148 , FY23: -188) | ||
・Improvement of RD expense and head office expense +213 Million (FY24: -843, FY23: -1,057) | ||||
・Difference of operating income +895 Million | ||||
Profit before tax | - 297Million | ・Gains / Losses related to CEJ Fund -719 Million (FY24: 71 Million, FY23: 790 Million) | ||
YoY + 269 Million | ・YoY Financial income/Expense mainly from gain from investment +112 Million | |||
(FY24: 356 Million - FY23: 245 Million = +112 Million) | ||||
※ Core Operating Profit = Operating profit - gains/losses due to non-recurring factors | ・Decrease in investment profit due to equity method | -19 Million | ||
(Foreign exchange gains/losses, impairments, and other one-time gains/losses)
2
Consolidated results: Revenue/Operating profit (Margin)
Sales of treatment services mainly RHG (US) continued to increase, and operating losses improved Group-wide operating income also improved from the previous year
(Unit : Millions of yen) | 2023/3Q | 2024/3Q | +/- | +/- % |
Product rental | Revenue | 1,294 | 1,302 | +8 | +0.6% |
Operating profit (Margin %) | 597 (46%) | 525 (40%) | -72 (-6pt) | -12.1% | |
Treatment Service | Revenue | 1,239 | 1,345 | +106 | +8.5% |
Operating profit (Margin %) | -351 (-28%) | -101 (-7%) | +250 (+21pt) | - | |
New Business | Revenue | 685 | 522 | -163 | -23.8% |
Expansion | Operating profit (Margin %) | -185 (-27%) | -155 (-30%) | +30 (-3pt) | - |
RD expenses and | Adjusted amount | -1,664 | -978 | -686 | - |
head office expenses | |||||
Consolidated total | Revenue | 3,219 | 3,169 | -49 | -1.5% |
(IFRS) | Operating profit (Margin %) | -1,603 (-50%) | -708 (-22%) | +895 (+28pt) | - |
• Product rental：Revenue from rental of the Group's products（includes revenue from sales) | |||||
* Amount of operating profit or loss, which is revenue minus operating expenses, for each business | • Treatment service：Revenue from treatment services provided through the Group's facilities (including service fees in Robocare Centers) | ||||
* Adjusted amount included R&D expenses, head office administrative expenses, other income and expenses, etc. | • New business expansion：Revenue from the Group's new business (e.g. subsidiary in Mobility and Sleeping App) | ||||
3 |
Revenue by business types & geographical region (Matrix)
RHG (US) treatment service continues to grow steadily
Declining trend in LeyLine (Germany), ASO (Japan) new business expansion
(Unit : Millions of yen) | Japan | EMEA | APAC | AMER | Total | YoY |
Top：2024 3Q YTD | ||||||
(Bottom：2023 3Q YTD) |
Product rental | 684 | 201 | 388 | 28 | 1,302 | +8 |
(676) | (226) | (346) | (46) | (1,294) | (+1%) | |
Treatment Service | 96 | 44 | - | 1,205 | 1,345 | +106 |
(107) | (40) | (1,091) | (1,239) | (+9%) | ||
New business | 186 | 337 | - | - | 522 | -163 |
Expansion | (281) | (404) | (685) | (-24%) | ||
Total | 966 | 582 | 388 | 1,233 | 3,169 | -49 |
(1,065) | (670) | (346) | (1,137) | (3,219) | (-2%) | |
YoY | -99 | -88 | +42 | +96 | ||
(-9%) | (-13%) | (+12%) | (+8%) | |||
Domestic | Foreign | |||||
Revenue to sales ratio | 30% | 70% | 100% | |||
AMER ：North, Central and South America |
EMEA : Europe, the Middle East and Africa
APAC : Asia-Pacific *Excluding Japan
4
Revenue from rental and sales (by product)
Steadily increase of sales of HAL for Medical Use Lower Limb Type towards new facility in Japan
Increased revenue outside Japan due to installing HAL Lower Limb type, HAL Single Joint Type, etc. to Social Security Organization, Malaysia.
(Unit : Millions of yen) | Type of product | Japan | Outside Japan | Total |
Top：2024 3Q YTD | ||||
(Bottom：2023 3Q YTD) | ||||
Medical HAL Lower Limb Type | 278 | 410 | 687 | |
(247) | (397) | (644) | ||
Cybernics Treatment | Non-medical HAL lower Limb Type | 118 | - | 118 |
（Functional improvement | ||||
(122) | (122) | |||
and regeneration） | HAL Single Joint Type | 65 | 87 | 151 |
(68) | (77) | (144) | ||
Well-being and care | HAL Lumbar Type | 78 | 66 | 145 |
(86) | (74) | (160) | ||
HAL Lumbar Type | 29 | - | 29 | |
Labor Support | (32) | (32) | ||
Mobile robot (CL02 etc.) | 54 | - | 54 | |
(83) | (83) | |||
Other (Acoustic X, Other products) | 63 | 55 | 118 | |
(39) | (70) | (110) | ||
Total | 684 | 618 | 1,302 | |
(676) | (618) | (1,294) |
5
Disclaimer
This presentation contains forward-looking statements concerning CYBERDYNE, Inc. and its Group's future plans, strategies and performance. Forward-looking statements contained in this presentation are based on information currently available and on certain assumption redeemed rational at the time of creation of this presentation. As such, due to various risks and uncertainties, the statements and assumption does not guarantee future performance, may be considered differently from alternative perspectives and may differ from the actual result.
Further, this presentation contains statements and information regarding corporate entities other than those belonging to the CYBERDYNE group, which have been complied from various publicly- available sources. CYBERDYNE does not verify nor guarantees accuracy and appropriateness of those information.
6
7